Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans

The objective of this study was to determine whether warfarin dosing algorithms developed for Caucasians and African Americans on the basis of clinical, environmental, and genetic factors will perform better than an empirical starting dose of 5 mg/day. From April 2002 through December 2005, 259 subjects (Caucasians and African Americans) who started using warfarin were prospectively followed until they reached maintenance dose. The Caucasian algorithm included 11 variables (R2 = 0.43). This model (which predicted 51% of the doses to within 1 mg of the observed dose) performed better than 5 mg/day (which predicted 29% of the doses to within 5 ± 1 mg). The African‐American algorithm included 10 variables (R2 = 0.28). This model predicted 37% of the doses to within 1 mg of the observed dose, representing a small improvement compared with 5 mg/day (which predicted 34% of the doses to within 1 mg of 5 mg/day). These results were similar to the results we obtained from testing other published algorithms. The dosing algorithms explained <45% of the observed variability in Caucasians, and the algorithms performed only marginally better for African Americans when compared with giving 5 mg empirically.

[1]  P. Deloukas,et al.  Association of warfarin dose with genes involved in its action and metabolism , 2006, Human Genetics.

[2]  M. Margaglione,et al.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005, Blood.

[3]  Howard L McLeod,et al.  Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin , 2003, Thrombosis and Haemostasis.

[4]  M. Margaglione,et al.  Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. , 2004, Haematologica.

[5]  M. Caldwell,et al.  Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. , 2004, Pharmacogenetics.

[6]  S. Fihn,et al.  The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin , 1996, Annals of Internal Medicine.

[7]  C. Thorn,et al.  Warfarin Response and Vitamin K Epoxide Reductase Complex 1 in African Americans and Caucasians , 2007, Clinical pharmacology and therapeutics.

[8]  Peter Wood,et al.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.

[9]  E. Hylek,et al.  Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. , 2005, Chest.

[10]  M. Ritchie,et al.  Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans , 2006, Pharmacogenetics and genomics.

[11]  C. Thorn,et al.  Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. , 2007, Pharmacogenomics.

[12]  V. Dolžan,et al.  The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement , 2006, Thrombosis and Haemostasis.

[13]  I. Ieiri,et al.  Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. , 2003, Blood.

[14]  S. Hunt,et al.  Common VKORC1 and GGCX polymorphisms associated with warfarin dose , 2005, The Pharmacogenomics Journal.

[15]  M. Rieder,et al.  Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.

[16]  J. Goldstein,et al.  Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans. , 2007, Personalized medicine.

[17]  Kevin Weiss,et al.  Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. , 2017, Annals of internal medicine.

[18]  S. Moll,et al.  Monitoring Warfarin Therapy in Patients with Lupus Anticoagulants , 1998, Annals of Internal Medicine.

[19]  D. Conrad,et al.  A worldwide survey of haplotype variation and linkage disequilibrium in the human genome , 2006, Nature Genetics.

[20]  K. Fahrbach,et al.  Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. , 2004, Chest.

[21]  E. Lange,et al.  Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation , 2006, Journal of Medical Genetics.

[22]  C. Thorn,et al.  Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans , 2008, The Pharmacogenomics Journal.

[23]  K. Klinger,et al.  Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. , 1993, Human molecular genetics.

[24]  A. Wu,et al.  Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. , 2008, Pharmacogenomics.

[25]  S. Thompson,et al.  Factors affecting the maintenance dose of warfarin. , 1992, Journal of clinical pathology.

[26]  G. Guyatt,et al.  The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy , 2004 .

[27]  J. Hirsh,et al.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[28]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[29]  J. Hirsh,et al.  Comparison of 5-mg and 10-mg Loading Doses in Initiation of Warfarin Therapy , 1997, Annals of Internal Medicine.

[30]  B. Horne,et al.  Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.

[31]  T. Lindahl,et al.  Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records , 2006, Journal of thrombosis and haemostasis : JTH.

[32]  Howard L McLeod,et al.  Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype , 2005, Thrombosis and Haemostasis.

[33]  Deborah A. Nickerson,et al.  Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans , 2003, Nature Genetics.

[34]  Jon Emery,et al.  CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: A HuGEnet™ systematic review and meta-analysis , 2005, Genetics in Medicine.

[35]  D. Cosh,et al.  Prospective evaluation of a flexible protocol for starting treatment with warfarin and predicting its maintenance dose. , 1989, Australian and New Zealand journal of medicine.